Altium Capital
Crossover fundNew York · Seed–Growth · 7 people tracked
Find your way into Altium Capital
1,636 people in our graph share verified history with the Altium Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Altium Capital Management provides growth capital to private and public healthcare companies developing novel technologies for human health. Its investment universe centers on therapeutics within private ventures, small-cap and micro-cap public companies, seeking firms with transformative catalysts ahead, many raising institutional capital for the first time. The firm supports early-stage ventures in pre-clinical development phases, aiming for long-term partnerships and participation across multiple financing rounds. Altium also helps companies attract additional capital through its network of like-minded investors, relying on rigorous research and due diligence to invest with a long-term horizon in promising new technologies.
Source: firm website, verified Aug 7, 2026.
Team · 7 people
from the firm's website & curated
What they invest in
from 11 of 17 portfolio companiesBiotech ×10Healthtech ×7Deep Tech ×4Medical Devices ×4AI & Machine Learning ×2Digital Health ×2
HQs:United States×5
Investments · 17 tracked
founders shown can be your intro pathBy year:2025 · 12021 · 12 dated
Hyperfine develops diagnostic imaging and data solutions for patient care.
AI & Machine LearningDeep TechHealthtechMedical Devices
Jonathan Rothberg(Founder)
Co-investorsColle Capital PartnersDolby Family Ventures
Opus Genetics (formerly Ocuphire) is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies and other treatments for inherited retinal diseases (IRDs) and other retinal and refractive disorders.
BiotechDeep TechDigital Health
Co-investorsCapital Midwest FundID Ventures
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAvego BioScience CapitalPontifax Venture CapitalAmzak HealthDelos CapitalDomain Partners+7 more
Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis.
BiotechHealthtechTel Aviv
Adi Mor(Executive Officer, Director)inAdi Mor George(Executive Officer, Director)Jill Quigley(Director)inSigal Fattal(Executive Officer)inMatthew Frankel(Executive Officer)inArnon Aharon(Executive Officer)in
Co-investorsOrbiMed
eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
BiotechDeep TechMedical Devices
Mike Curtis, Ph.D.(President & Chief Executive Officer)
Co-investorsAlta PartnersEisai Innovation, Inc.Fresenius Medical Care VenturesKhosla VenturesLux Capital
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in
Co-investorsClavystBioDecheng CapitalDroia VenturesFrazier Life SciencesKiwoom InvestmentMuirwoods Ventures+2 more
Immunovant is a clinical-stage immunology company developing targeted therapies based on anti-FcRn technology for people with autoimmune diseases.
BiotechHealthtechMedical DevicesNew York, US
Christopher Van Tuyl(Executive Officer)Michael Geffner(Executive Officer)inPete Salzmann(Executive Officer, Director)inJay Stout(Executive Officer)inMelanie Gloria(Executive Officer)inEva Renee Barnett(Executive Officer)
Palisade Bio develops a PDE4 prodrug platform for treating immune, inflammatory, and fibrotic diseases, with improved pharmacokinetics and tolerability compared to traditional PDE4 inhibitors.
BiotechMedical DevicesCarlsbad, US
I. Richard Garr(Executive Officer, Director)Karl Johe(Executive Officer, Director)Robert McRae(Executive Officer)inHerbert Slade(Executive Officer)J.D. Finley(Executive Officer, Director)JD Finley(Chief Executive Officer)
Quoin Pharmaceuticals is a pharmaceutical company developing therapeutic products for rare diseases, with a lead candidate, QRX003, in clinical trials for Netherton Syndrome.
BiotechHealthtechAshburn, US
Michael Myers(Executive Officer, Director)Denise Carter(Executive Officer, Director)inMICHAEL MEYERS(Executive Officer, Director)Sally Bridget Lawlor(Executive Officer)Eyal Leibovitz(Executive Officer)Shai Yarkoni(Executive Officer, Director)
Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology.
BiotechDigital HealthHealthtech
David Happel(Chief Executive Officer & Director)Andreas Grauer(Chief Medical Officer)inThierry Chauche(Chief Financial Officer)Marie O'Farrell(Chief Scientific Officer)Elizabeth Rozek(Chief Legal & Administrative Officer)
Co-investorsHM Venture PartnersKleiner PerkinsNew Enterprise Associates (NEA)
BiotechNew York, US
Raj Mehra(Chief Executive Officer)Michael Golembiewski(Chief Financial Officer)inBRIAN DORSEY(Executive Officer)CATHERINE BOVENIZER(Executive Officer)NEIL MORTON(Executive Officer)
BoardBrian Lian(Director)
Co-investorsSanofi VenturesDolby Family Ventures
Exits · 1
IPOs and acquisitions across the tracked portfolioHyperfineNASDAQ: HYPR
Portfolio news
latest coverage across their companiesChemomab · stocktitan.net · Aug 13, 2026
Hummingbird Bioscience · fiercebiotech.com · Dec 19, 2025
Frequently asked questions
- How many investments has Altium Capital made?
- Altium Capital has 17 tracked investments, including 1 dated in the last 24 months.
- What stage does Altium Capital invest at?
- Altium Capital invests at the Seed, Series A, Growth stages.
- What sectors does Altium Capital focus on?
- Altium Capital focuses on Biotech, Crypto & Web3, Digital Health, Healthtech, Medical Devices.
- Where is Altium Capital located?
- Altium Capital is headquartered in New York, US.
- Who does Altium Capital co-invest with?
- Altium Capital most often shares deals with Khosla Ventures, Kleiner Perkins, Lux Capital, among 23 tracked co-investors.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Brightstone Venture Capital manages a $100 million venture fund focused on early-growth stage technology and life-science investments.
NJF Capital is the venture investment arm of NJF Holdings, the private investment group founded by Nicole Junkermann. It backs transformative entrepreneurs building industry-defining technologies with global scale potential.
Olive Tree Capital invests in technology and life sciences companies, backing entrepreneurs across healthcare, fintech, enterprise, AI/ML, and frontier technology sectors.